Aclaris Therapeutics, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Aclaris Therapeutics, Inc. (ACRS) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $0 as of 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2020-02-25
- 2019-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $0.00.
- 2018-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $0.00.
- 2017-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $36.00K.
- 2016-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $0.00.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2017-12-31 | $36.00K 10-K · filed 2019-03-18 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |